|Day Low/High||114.57 / 115.91|
|52 Wk Low/High||94.28 / 126.07|
The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.
Johnson & Johnson (JNJ), McKesson (MCK), Merck (MRK) and UnitedHealth (UNH) benefit from demographic trends and have solid fundamentals.
The health care sector's ties to the increasingly unpopular Affordable Care Act, plus an uncertain U.S. presidential picture, give some financial experts pause.
Doug Kass shares his thoughts on soup, insurance and Starbucks.
If the polls are right and Hillary Clinton wins the White House, these five stocks stand to get an immediate and long-lasting boost.
Jim Cramer ponders why M&A is just the start of the story and also wonders what a Democratic sweep would do to the markets.
The market's getting nervous about the prospect of a Democratic landslide, says Jim Cramer.
For starters, trouble for banks, drugs, energy and M&A.
Jim Cramer reflects on a dramatic day of selling on Wall Street that forever changed the industry.
THE SITE WILL OPEN WITH 240 EMPLOYEES WITH PLANS TO LOCATE 540 BY 2020
On this date 29 years ago, world stock markets crashed during a massive one-day selloff that came to be known as Black Monday.
Customer event will feature analysis of mass transfusion protocol implementation in the wake of Orlando attack
Stocks rally on Tuesday after a number of companies, including Netflix and Goldman Sachs, clear low quarterly expectations.
Stocks hold near session highs on Tuesday afternoon as a positive earnings report from Netflix boosts the Nasdaq.
JNJ is off 2.3% on heavy trade and is taking out a very solid support zone in the process. This nasty breakdown has further to go.
The health care giant says it can access foreign cash by borrowing against it. But it has little use for price controls.
U.S. stocks held higher as a series of positive earnings reports filtered in on Tuesday. Netflix boosted the Nasdaq, while Goldman Sachs pushed the Dow Jones Industrial Average higher.
Stocks trade higher on Tuesday as a series of positive earnings reports from the likes of Netflix and Goldman Sachs filters in.
Johnson & Johnson (JNJ) posted 2016 third-quarter earnings results before Tuesday's open that beat analysts' expectations.
Stock futures hold higher on Tuesday as consumer inflation in September rises at a pace economists had expected.
Netflix's streaming subscriber base in the third quarter grows by 3.57 million sequentially to 86.7 million, topping guidance; Visa CEO Charlie Scharf to resign; U.S. stock futures are rising.
J&J reiterates its full-year sales guidance of between $71.5 billion and $72.2 billion and says it sees full-year adjusted per-share earnings of between $6.68 and $6.73.
On Tuesday, October 18, Goldman Sachs (GS) and Yahoo! (YHOO) release quarterly results.
Johnson & Johnson is undergoing a transformation in its product portfolio. These three ETFs may benefit if investors are excited about third-quarter results.
A study of analyst recommendations at the major brokerages shows that Johnson & Johnson is the #16 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, JNJ claims the #283 spot.
Investors had reduced expectations for Celgene's experimental pill for Crohn's disease, which makes the new clinical data released Sunday night look all right, although doubts will persist.